Special Issue

Porcine Vaccines: Enhancing Health, Productivity, and Welfare

Message from the Guest Editor

We are delighted to invite you to submit your next publication to the journal Vaccines for a Special Issue entitled "Porcine Vaccines: Enhancing Health, Productivity, and Welfare". Porcine reproductive and respiratory syndrome, porcine viral diarrhea, African swine fever, circovirus-related diseases, and others, seriously harm and restrict the healthy development of the pig industry. In recent years, many variants of porcine viruses have emerged and immunologically escaped from the current available vaccines, causing new challenges in the prevention of porcine diseases and required the updating of existing vaccines, antigens, or adjuvants. DIVA vaccines, multivalent vaccines, and antigen-precise-designed vaccines are the focus of current porcine vaccine research. In addition, oral, spray, and other needle-free vaccination delivery methods have seen strong demand for animal disease control in the future.

This Special Issue will focus on porcine vaccines, including vaccine design, development, effect evaluation, small-animal replacement models, DIVA, vaccination delivery methods, and so on. Original research articles, and comprehensive reviews are welcome.

Guest Editor

Dr. Tongqing An

State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China

Deadline for manuscript submissions

closed (31 January 2025)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/181307

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

